AbsciNASDAQ: ABSI

VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024.

Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033.

VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

Absci Corporation (NASDAQ:ABSI ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Steven Mah - TD Cowen Srikripa Devarakonda - Truist George Farmer - Scotiabank Scott Schoenhaus - KeyBanc Operator Good day and thank you for standing by. Welcome to the Absci Second Quarter 2024 Business Update Conference Call.

Absci Corporation (ABSI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.27 per share a year ago.

Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships

VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stock to Ms. Shelby Walker in connection with her employment as Absci's Chief Legal Officer. The inducement grant was previously approved by Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to Ms. Walker's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

ABSCI Corporation's stock experienced a significant increase in the last trading session, accompanied by above-average trading volume. However, the recent changes in earnings estimates may not lead to additional price growth in the short term.

Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.